摘要
目的观察疏风宣肺祛痰法治疗支气管哮喘慢性缓解期风痰哮证的临床疗效。方法选取45例慢性缓解期支气管哮喘属风痰哮证患者，将其随机分为对照组（20例）和观察组（25例）。对照组予以信必可都保，观察组在对照组的基础上加以服用疏风宣肺祛痰中药，分别于治疗前及治疗4周后记录患者症状、体征及ACT评分，并统计积分结果、观察疗效及两组的不良反应。结果观察组总显控率为88％，对照组显控率为60％；两组治疗前后症状积分比较有显著性差异（P〈0．05），观察组优于对照组；两组治疗前后ACT评分比较有显著性差异（P〈0．05），且观察组优于对照组；两组治疗前后FEV1％、PEF、FEF25和FEF50比较有显著性差异（P〈0．01），观察组FEVI％、PEF及FEF50改善程度优于对照组；观察组无不良反应。结论疏风宣肺祛痰法治疗慢性缓解期支气管哮喘风痰哮证疗效显著，可改善哮喘患者的肺功能，有效控制哮喘再发，且不良反应少，值得临床推广应用。
Objective To observe the clinical effect of expelling phlegm by dispersing wind and dispersing the lung to treat the patients with the wind and phlegm of bronchial asthma in chronic remission stage. Methods 45 cases of patients with bronchial asthma were randomly divided into control group （ n=20 ） and observation group （ n=25 ） .The patients in control group were given Symbicort twice a day. The patients in observation group were given the Chinese prescription based on the expelling phlegm by dispersing wind and dispersing the lung to ventilate the lungs. Results Observation group＇ s significant control rate was 88% and the control group＇ s was 60% the syndrome and ACT integration were of obvious significance in the two separate groups （ P〈0.05 ） , while the score in the observation group was better than the control group the numerical value ofFEV1%, PEF, FEF25 and FEF50 were of obvious significance in the two separate groups （ P〈0.05 ） , while the improvement ofFEV1%, PEF and FEF50 in the observation group were better than the control group, there was no untoward effects in observation group. Conclusion The expelling phlegm by dispersing wind and dispersing the lung is effective in treating the patients with the syndrome of wind and phlegm of bronchial asthma, reducing the rehpse ofit with less untoward effects and worth spreading in clinical application.
出处
《浙江临床医学》
2018年第6期1069-1070,1072,共3页
Zhejiang Clinical Medical Journal
关键词
支气管哮喘
疏风宣肺祛痰法
风痰哮证
临床观察
Bronchial asthma
Expelling phlegm by dispersing wind and dispersing the lung
The syndrome of wind and phlegm ofasthma
Clinical research
